1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

29 Feb 2024
Admin
News Article

Virtual Incision Gains FDA Marketing Authorization

Virtual Incision receives US FDA marketing authorization for miniaturized robotic-assisted surgery device

Overview

Virtual Incision, a cultivate (MD) portfolio company, has been received marketing authorization of the MIRA Surgical System (MIRA) from the US FDA. This marks a significant milestone as MIRA becomes the first miniaturized robotic-assisted surgery device in the world approved for adult colectomy procedures.

Words from Virtual Incision

R. Sean Churchill, MD, MBA, managing director of cultivate (MD), expressed enthusiasm for the US FDA approval. ""Cultivate (MD) Capital Funds is proud to have partnered with Virtual Incision Corporation along their developmental journey. We have long recognized the need for mainstream robotics in medicine that can simultaneously provide minimally invasive surgery with system portability allowing use in large university based hospital systems as well as smaller community hospitals, all in a cost effective, efficient manner. Virtual Incision Corporation accomplished these goals and has redefined the future of robotic surgery.""

Aim for Robotic Surgery Integration

Virtual Incision views MIRA's innovative design as a potential game-changer in the realm of surgical technology.
With its compact size (weighing less than two pounds) and a user-friendly tray-to-table setup, MIRA is designed to with the hopes of enhancing operating room efficiency.
This innovative approach aims to facilitate the integration of robotic surgery in a wider range of healthcare settings, potentially overcoming the logistical challenges associated with the large surgical robots that are currently available.

Director’s Words from Virtual Incision

"We have been in awe of watching this incredible innovative technology and team for years, creating and thinking outside of the box,"" said David Blue, Director of cultivate (MD) Capital Funds. ""These miniature robots will be the future, and they will continue to amaze the rest of the surgical robotics world, and it will be fun seeing them lead us into this new world! We are so excited and honored to be on this journey with Virtual Incision!""

Mira’s Commercial Entry

With US FDA authorization in hand, Virtual Incision is set to initiate MIRA's commercial rollout in select centers in the United States.

Mira’s Future Indications

MIRA's broader commercialization and expansion of its roadmap for future indications includes gynecology, general surgery, urology and other soft tissue and solid organ surgery.

Additionally, a new iteration of the technology tailored to general surgery is in design and expected to be used in a first-in-human study outside the US later this year.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!